MCK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
McKesson is not a strong buy right now for a beginner long-term investor, even with $50,000-$100,000 available. The stock has solid fundamentals and analysts remain broadly positive, but the current setup is mixed: the trend is not cleanly bullish, insider and congress activity lean negative, and there is no fresh catalyst from news. Because you said the investor is impatient and unwilling to wait for optimal entry points, I would not call this a buy today. I would hold and wait for a clearer technical reset or a stronger confirmation of momentum before committing capital.
Current price is 787.70, slightly above the previous close of 786.30, with a positive regular-session move of 2.37%. Momentum is improving in the short term because MACD histogram is positive and expanding, which supports near-term upside. However, the moving average structure is bearish (SMA_200 > SMA_20 > SMA_5), showing the broader trend is still not fully aligned for a high-conviction entry. RSI_6 at 68.3 is elevated and near overbought territory, suggesting the stock is not offering an ideal fresh entry here. Price is currently near resistance at R1 780.687 and below R2 790.813, so upside may be somewhat stretched in the immediate term.
Analysts are still mostly bullish, with multiple Buy/Outperform ratings retained. UBS raised its target to $1,050, and William Blair initiated coverage with an Outperform rating, citing a durable moat and specialty-led growth upside. The company is viewed as benefiting from demographic tailwinds and rising specialty medicine adoption. Options sentiment is also mildly bullish, and the stock remains supported by a strong market reputation in healthcare distribution.
There was no news in the past week, so there is no fresh event-driven catalyst. Insider selling has increased 144.45% over the last month, which is a negative signal. Congress trading data shows one sale and no purchases in the last 90 days, also leaning cautious. Several analysts lowered price targets recently, and the technical trend is not fully aligned for a clean breakout. Comparable candlestick pattern data suggests near-term downside bias of -0.43% next day, -1.29% next week, and -0.62% next month.
Financial snapshot data was unavailable due to an error, so latest quarter revenue and earnings details cannot be directly assessed. Based on analyst commentary, the latest quarter appears to have been mixed, but FY27 guidance and the long-range plan were viewed as positives. The latest quarter season is not explicitly provided in the dataset.
Wall Street remains constructive overall: Citi cut its target to $945 but kept Buy, UBS raised to $1,050 and kept Buy, JPMorgan kept Overweight, BofA kept Buy, and William Blair initiated Outperform. However, target cuts from Deutsche Bank, Baird, Evercore ISI, and BofA show some valuation compression and cautious tone after a mixed quarter. Overall, pros still favor the stock, but the consensus has become more selective, with optimism tempered by recent target reductions.
